Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Apixaban + digoxin** is a combination of two active pharmaceutical ingredients: apixaban, an oral anticoagulant that is a direct and highly selective inhibitor of factor Xa, and digoxin, a cardiac glycoside that inhibits the Na+/K+ ATPase pump, increasing intracellular calcium and improving cardiac contractility. Apixaban is used in prevention and treatment of thromboembolic events (including stroke and deep vein thrombosis) in conditions such as nonvalvular atrial fibrillation, and after major orthopedic surgery. Digoxin is primarily used for heart failure and certain arrhythmias, such as atrial fibrillation. There is no significant pharmacokinetic interaction between apixaban and digoxin; both can be coadministered safely under appropriate medical supervision.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on apixaban + digoxin.